GSK spin-off NeRRe raises £23 million

by | Jan 5, 2017 | | 0

UK clinical-stage group NeRRe Therapeutics has raised £23 million advance its unique neurokinin receptor antagonist pipeline towards late-stage clinical development.

Read More